Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Kyowa Hakko Kirin — FY2012 Earnings Presentation
19 slides from Kyowa Kirin's earnings presentation, Jan 31, 2013
Slide 1: Fiscal 2012 Results Meeting
Kyowa H K Hakko kk Ki Kirin i Fiscal 2012 Results Meeting (Fiscal year to December 31, 2012) January y 31,, 2013 Kyowa Hakko Kirin Co., Ltd. Statements on results, forecasts and R&D status contained in this presentation represent judgments based on information available at the current time. Actual r
Slide 2: Safe harbor statement
Safe harbor statement This document contains certain forward-looking statements relating to such items as the company’s company s (including its domestic and overseas subsidiaries) forecasts forecasts, targets and plans. These forward-looking statements are based upon information available to the co
Slide 3: Contents
Contents 1 Summary of FY2012 results 1. Executive Managing Officer Kazuyoshi Tachibana 1) Consolidated/Pharmaceutical/Bio-Chemical 2) Sales by core pharmaceutical product 2. Kyowa y Hakko Kirin Group p President and CEO Nobuo Hanai
Slide 4: Summary of FY2012 financial results
S Summary off FY2012 fi financial i l results lt Executive Managing Officer, Kazuyoshi Tachibana
Slide 5: Summary of FY2012 financial results
Summary of FY2012 financial results Net sales declined significantly due to the effects of removing the chemical business from consolidation Operating income* income achieved a record high for third consecutive year due to strong performance in the Pharmaceuticals business FY2012 (¥ bn) FY2011 FY201
Slide 6: Summary of FY2012 financial results
Summary of FY2012 financial results Sales of core products were steady despite effects of national health insurance drug price Revenues from technology for bio-similar related development also contributed to consolidated results Fiscal 2011 Fiscal 2012 FY2012 (¥ bn) vs. FY2011 results forecast resul
Slide 7: Pharmaceutical business: Analysis of sales changes
Pharmaceutical business: Analysis of sales changes Net sales (consolidated) Operating income (consolidated) FY 2011 results 229.3 FY 2011 41.3 Domestic Pharmaceuticals 0 (Non-consolidated) Gross profit +17.1 Revenues from exports (Non- +0.2 consolidated) Revenues from SG&A (excludes R&D expenses) -
Slide 8: Bio-chemical business: Analysis of sales changes
Bio-chemical business: Analysis of sales changes Net sales (consolidated) Operating income (consolidated) FY 2011 2.8 results 77.5 Domestic sales - 0.6 Overseas sales 0 -0.0 FY 2012 results 76.9 (¥bn) 億円 (¥bn) 70 75 80 Sales Gross profit ●Domestic sales (-¥0.6bn): ●Gross profit (-¥0.４bn): Significan
Slide 9: Please refer to accompanying Consolidated Financial Summary and Appendix
Please refer Pl f tto th the accompanying i C Consolidated lid t d Financial Summary y and Appendix pp documents
Slide 10: Kyowa Hakko Kirin Group
K Kyowa Hakko H kk Ki Kirin i GGroup Nobuo Hanai Hanai, President and CEO
Slide 11: FY 2012 H2: Achievements
FY 2012 H2: Achievements Domestic and overseas pipelines reached development milestones as planned New pipelines saw two drugs as FIRST IN HUMAN Domestic Launched Parkinson’s disease agent Apokyn ® Filed KW-2246 for cancer pain therapy currently in development Began phase II studies on KHK4827
Slide 12: Changes in development strategy
Changes in development strategy ARQ 197 Driving development of heptocellular cancer in a major Asian market Target Stage Status Remarks disease NSCLC EGFR-Wild Phase3 Discontinued Occurence of interstitial disease on combination trials NSCLC EGFR-Mut. Phase2 On going EGFR-Mut. common among Asians. G
Slide 13: Group mission and inquiries contact
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. If y you have anyy inquiries q regarding g g this p presentation p please call: Corporate Commun
Slide 14: Appendix
KYOWA KIRIN copyright© 2008 Kyowa Hakko Kirin Co.,Ltd. All Rights Reserved
Slide 15: Sales of core pharmaceutical products
Sales of core pharmaceutical products (¥ bn) Product FY2011 FY2012 2012/2011 FY2013 forecast change (%) Nesp 56.4 58.1 103 57.8 Espo 5.3 3.9 73 3.5 gp Regpara 11.5 13.4 116 14.1 Allelock 29.1 29.9 103 27.8 Patanol 11.4 10.2 90 11.4 Asacol 2.8 4.1 142 4.8 Gran 14.8 13.5 92 12.6 Fentos 3.1 4.6 148 5.5
Slide 16: Effects of foreign exchange
Effects of foreign exchange Forex rates FY2011 FY2012 Change /$ ¥80/$ ¥80/$ -¥0/$ /€ ¥111/€ ¥103/€ -¥8/€ /￡ ¥128/￡ ¥127/￡ -¥1/￡ (Period average) Effects of foreign exchange Impact during FY2012 (compared to previous year) Pharmaceutical Bio-Chemical Consolidated business business Net sales -¥0.2bn -
Slide 17: Pharmaceutical businesses in Asia
Pharmaceutical businesses in Asia Pharmaceutical business across Asia Consolidated subsidiaries MRs Net sales Products South Korea ¥2.9 bn Est. May 1991 27 Nesp,Gran,Renagel,Regpara Kyowa Hakko Kirin Korea Busulfex,Leunase､ Mitomycin Co Ltd Co.,Ltd. C,Nplate China ¥2.9 bn Est. Jun. 1997 124 Gran,Esp
Slide 18: Asian markets: Development and sales (1)
Asian markets: Development and sales (1) ◎: Launched ○: Approved ☆: Filed (As of January 24, 2013) Hong Korea China Taiwan Singapore Thailand Malaysia Philippines Indonesia Vietnam Kong Ｅｓｐｏ ◎ Ｎｅｓｐ ◎ Phase 2 ◎ ○ ◎ ◎ ◎ ○ Ａｒａｎｅｓｐ ◎ Ｒｅｎａｇｅｌ ◎ ◎ Ｇｒａｎ ◎ ◎ ◎ ◎ ◎ ◎ ○ ◎ Ｐｅｇｌａｓｔａ ◎ ◎ ◎ ◎ ○ Ｎｅｕｌａｓｔａ ○ ◎ Ｎｐｌａｔ
Slide 19: Asian markets: Development and sales (2)
Asian markets: Development and sales (2) ◎: Launched ○: Approved ☆: Filed (As of January 24, 2013) Hong Korea China Taiwan Singapore Thailand Malaysia Philippines Indonesia Vietnam Kong Ｍｉｔｏｍｙｃｉｎ Ｃ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ Ｌｅｕｎａｓｅ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ Ｃｏｎｉｅｌ ◎ ◎ ◎ ◎ Ａｌｌｅｌｏｃｋ ◎ ◎ Ｓａｎｃｕｓｏ ○ ☆ ☆ ☆ ＡＲＱ １９７ Ph